A Modern GCP Framework Powering Decentralized, Real-World and Pragmatic Trial Innovation

ICH GCP E6 (R3) Annex 2 has officially been adopted (June 3, 2026) and published (July 2026), marking a major milestone in the global evolution of Good Clinical Practice.

As clinical trials evolve toward digital, decentralized, and complex models, Annex 2 equips sponsors with the structure and regulatory clarity needed to move forward with confidence. Together with the E6 (R3) Principles and Annex 1, it establishes a unified, modern GCP framework fit for today's trial realities.

As your trusted CRO partner, QbD wants to break down what Annex 2 means for you – and how we're already aligned to support your next-generation trials.

Why Annex 2 Matters Now

Clinical trials have transformed dramatically over the past decade. Annex 2 reshapes how sponsors and investigators plan, execute and oversee clinical trials that incorporate decentralized elements, pragmatic features, digital endpoints or real-world data sources. It provides long-awaited regulatory clarity for trial models that fall outside traditional site-centric designs, ensuring that innovation can advance without compromising GCP expectations.

What Annex 2 Covers

1. Decentralized Trial Elements

Annex 2 formally integrates decentralized and hybrid trial activities into GCP expectations such as trial-related activities conducted outside the investigator's location. These include:

• Remote interactions
• Home-based procedures
• Digital tools for data capture
• Technology-enabled participant engagement

These elements are now recognized as legitimate, GCP-compliant methodologies – provided they are implemented with appropriate oversight.

2. Pragmatic Trial Designs

Annex 2 supports designs and conduct of the trial that integrate aspects of usual clinical practice - "Usual clinical practice" referring to the established day-to-day processes and procedures applied by healthcare professionals when caring for patients.

This includes:

• Eligibility criteria that reflect usual clinical practice in that patient population
• Streamlined data collection
• Minimizing complexity of trial conduct
• Integration into routine care settings

This is a major opportunity for sponsors seeking faster recruitment, more representative populations, and more generalizable evidence.

3. Use of Real-World Data (RWD)

Annex 2 introduces clear expectations for incorporating RWD in clinical trials from:

• Electronic Health Records (EHRs)
• Registries
• Claims databases
• Digital Health Devices

Sponsors must ensure RWD is:

• Fit for purpose in the clinical trial
• Reliable and Traceable
• Governed appropriately

This is a significant step toward regulatory acceptance of RWD in clinical trials.

4. Proportionate, Risk-Based Oversight

Annex 2 reinforces flexible oversight tailored to the trial's design and data sources. This includes:

• Adjusted monitoring intensity
• Fit-for-Purpose quality controls
• Proportionate Risk Management

Monitoring, data review, and quality management can be tailored to the trial's design, data sources, and decentralization level – reducing burden while maintaining compliance.

This aligns perfectly with modern Quality-by-Design (QbD) principles.

What Annex 2 Means

Annex 2 enables more flexible, efficient, and participant-friendly trials – but it also raises expectations around data quality, technology governance, and vendor oversight.

Annex 2 updates ICH GCP to reflect how clinical trials are actually conducted today – increasingly decentralized, enriched with real-world data, and designed with pragmatic elements that align more closely with routine care. It provides a unified, proportionate framework that supports these modern approaches while preserving the foundational GCP principles of participant safety, data integrity and ethical conduct.

The guidance clarifies how digital tools, remote procedures, routine-care workflows and diverse data sources can be integrated into compliant trial designs. Annex 2 emphasizes that digital platforms, decentralized service providers, and data-generating technologies must be governed with documented controls, risk assessments, and ongoing performance evaluation.

How QbD Can Support You Under E6 (R3) Annex 2

Our teams help you design studies that balance scientific rigor with real-world feasibility. Our teams combine operational excellence with modern trial innovation — ensuring your studies remain compliant, efficient, and participant centric.